Why did Cynata Therapeutics (ASX:CYP) decide to end the CYP‑001 trial early?

Cynata Therapeutics (ASX:CYP) decided to end the CYP‑001 Phase 2 trial early because the primary evaluation showed no significant differences in response or survival outcomes between the active treatment and control groups. The company said this result did not support continuing follow‑up to the originally planned December 2027 end date.

What are the key efficacy results from Cynata Therapeutics’ (ASX:CYP) CYP‑001 Phase 2 aGvHD trial?

The CYP‑001 Phase 2 trial by Cynata Therapeutics (ASX:CYP) reported a Day 28 overall response rate of 57.7% in the active arm versus 54.8% in control, with p‑values above 0.5 for all key endpoints, indicating no statistically significant treatment advantage at Days 28 or 100.

How is safety described in Cynata Therapeutics’ (ASX:CYP) CYP‑001 Phase 2 trial?

Cynata Therapeutics (ASX:CYP) stated that there were no safety concerns identified in the CYP‑001 Phase 2 trial and that the adverse event profile was similar between the active and control groups, suggesting the treatment was generally tolerated but without added efficacy versus standard care.

What does the voluntary suspension mean for Cynata Therapeutics (ASX:CYP) shareholders?

The voluntary suspension for Cynata Therapeutics (ASX:CYP) means trading in its shares is paused while the company prepares to release Phase 3 SCUlpTOR results for CYP‑004 in knee osteoarthritis later this week. The company indicated it will update the market and seek to lift the suspension once those data are available.

How does the CYP‑001 result fit into Cynata Therapeutics’ (ASX:CYP) broader strategy?

Cynata Therapeutics (ASX:CYP) said the disappointing CYP‑001 Phase 2 result follows earlier positive Phase 1 data in aGvHD but that it will now focus on its broader Cymerus cell therapy pipeline, including the Phase 3 CYP‑004 osteoarthritis study, which the company expects will be a key determinant of future development priorities.

Image for illustrative purposes only. Not a real photo.

Cynata posts flat Phase 2 CYP‑001 GvHD data

Written by Liezl GambePublished Jun 17, 2026, 5:59 AM

· Cynata Therapeutics (ASX:CYP) reported no efficacy advantage for CYP‑001 over control in a Phase 2 aGvHD trial.

· The company found similar safety and response rates between treatment and control groups and will end the study early.

· Cynata (ASX:CYP) will stay in voluntary suspension while it awaits Phase 3 CYP‑004 osteoarthritis trial results expected this week.

Cynata Therapeutics (ASX:CYP) reported primary evaluation results from its Phase 2 trial of CYP‑001 in high‑risk acute graft versus host disease, showing no significant difference in response rates compared with the control group.

The company said safety was similar between treatment arms and that the study did not meet its primary or key secondary endpoints when compared with standard steroid therapy plus placebo.

“We are exceptionally disappointed with this outcome,” said Cynata Therapeutics (ASX:CYP) CEO and Managing Director Dr Kilian Kelly.

The trial enrolled 65 patients across Australia, the United States and Europe, randomising them to receive steroids plus CYP‑001 or steroids plus placebo, with 57 patients included in the primary analysis after eight withdrew before receiving study treatment.

Cynata stated that the 100‑day primary evaluation period has been completed and that, in light of the flat efficacy result, it has decided to terminate the remaining follow‑up phase early, ahead of the originally planned December 2027 end date.

Following the announcement the Cynata Therapeutics (ASX:CYP) share price was unchanged as the stock remains in voluntary suspension.

Cynata described CYP‑001 as its Cymerus iPSC‑derived mesenchymal stem cell product for intravenous use and said it will now focus on the Phase 3 SCUlpTOR trial of CYP‑004 in knee osteoarthritis, with results expected later this week.

Cynata posts flat Phase 2 CYP‑001 GvHD data

Frequently asked questions

Assets related to this article